Cipher’s board of directors has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products.
Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.
Craig Mull is currently the managing director of 1207407 Ontario Limited and is responsible for overseeing a variety of its investments which includes the entity’s interest in the Corporation. Mr. Mull is also the founder and Chief Executive Officer of Typhon Group Ltd, a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area. He served as Director of Corporate Development, Vice President and Chief Operating Officer of CML from 1989 to 2004 where he was instrumental in the company’s growth. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from less than $20 million in annualized revenue to over $235 million. Prior to joining CML, Mr. Mull held the role of Sales and Marketing Manager at Baxter Corporation. Mr. Mull received an HBA from Ivey Business School at the University of Western Ontario.
Mr. Deboeck is currently the Founder, Vice-President and General Manager of Galephar Pharmaceutical Research, Inc. and President and Principal Investigator of Galephar Research, Inc. (collectively, “Galephar”). Galephar is a Puerto Rico-based pharmaceutical research company with oral and pulmonary drug delivery technology, formulation, and manufacturing expertise. Galephar has developed and licensed to Cipher various pharmaceutical products and manufactures products for Cipher.
Mr. Deboeck has more than 45 years of experience in the pharmaceutical field of drug delivery. He received his education as a chemical engineer from the Institut Meurice Chimie, Brussels, Belgium and a Galenic Pharmacy degree from the University of Liege, Belgium.
Mr. Godin is the former Head of Equities at Montrusco Bolton Investments Inc., a Montreal-based investment firm, and previously sat on its board of directors. He was also a member of the Management Committee of Montrusco. Prior to joining Montrusco in 2001, Mr. Godin worked for Merrill Lynch Canada where he was a director and senior equity research analyst. He also worked for Midland Walwyn Capital and CTI Capital.
Mr. Godin holds a Bachelor of Business Administration from Université du Québec à Montréal and a Master of Science in Administration specialized in Finance from HEC Montréal.
John Mull, MD, is CEO of Typhon Group Limited, a private equity capital corporation. Dr. Mull is the founder and former CEO of Cipher Pharmaceuticals Inc., as well as CML HealthCare Inc., Pharma Medica Research Inc. and Starplex Scientific, Inc. In those capacities, he has been involved in more than 30 merger and acquisition transactions. Cipher and Pharma Medica were subsidiaries of CML prior to CML’s conversion to an income trust in 2004. At the time, CML was one of the largest operators of medical diagnostic and medical imaging facilities in Canada and the United States. Its peak market capitalization exceeded $1.4 billion. CML merged with LifeLabs Medical Laboratory Services in 2013.
Dr. Mull is a graduate of the Faculty of Medicine, University of Toronto, and completed his training in Anatomic and Clinical Pathology at the University of Michigan (Ann Arbor). He is certified in Pathology by the Royal College of Physicians and Surgeons and in Anatomic and Clinical Pathology by the American College of Physicians and Surgeons. His original investigative research work in those fields involved publication of 15 papers in various medical journals. Dr. Mull’s experience in practice as a staff pathologist at hospitals in South Western Ontario convinced him that healthcare providers required high-quality medical diagnostic services not then available. He founded CML in 1971 to address that need.
Ms. Steiner has over 20 years experience as an investment banker and strategic advisor working with healthcare and growth companies. She is Principal and Healthcare Lead for Origin Merchant Partners, a mergers & acquisitions advisory and investment banking firm, since January 2018. Prior to joining Origin, she was CFO for technology companies through capital raising and M&A transactions (2014 – 2016).
Previously Ms. Steiner was Managing Director for Nucleus GC (2002 – 2014), a boutique healthcare advisory firm, and led Healthcare Investment Banking for CIBC World Markets and Yorkton Securities. Ms. Steiner holds an MBA (Schulich School of Business at York University), MSc (Immunology) (McMaster University) and CPA, CA designation.
Mr. Wolkin is an accomplished investment banker and financial analyst with over 30 years of experience. Mr. Wolkin joined BMO Nesbitt Burns as a senior research analyst in 1983. He went on to serve as managing director in the Diversified Industries Group of BMO Capital Markets until January 2008. Most recently, Mr. Wolkin served as Executive Vice-President and Head of Investment Banking for Dundee Capital Markets. Mr. Wolkin has served on a number of public company and not-for-profit boards and currently serves as a director of Diamond Estates Wines & Spirits and Baylin Technologies Inc. He was the past President of the CFA Society of Toronto and has been a member of the Chartered Financial Institute since 1980. He is a member of the Institute of Corporate Directors.